A phase IIa study assessing BT7401 for cancer
Latest Information Update: 14 Jan 2020
At a glance
- Drugs BT 7401 (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 14 Jan 2020 New trial record
- 07 Jan 2020 According to a Bicycle Therapeutics media release, Cancer Research UK will fund and sponsor development of BT7401, a multivalent Bicycle CD137 agonist, through this study.